12 West Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

12 West Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,348	Closed	-$2.06M	–	16
2020 Q3	$2.06M	Hold	6,348	–	–	0.1%	16
2020 Q2	$2.31M	Hold	6,348	–	–	0.12%	15
2020 Q1	$1.35M	Hold	6,348	–	–	0.08%	17
2019 Q4	$2.61M	Hold	6,348	–	–	0.16%	13
2019 Q3	$2.24M	Hold	6,348	–	–	0.14%	14
2019 Q2	$3.19M	Hold	6,348	–	–	0.24%	14
2019 Q1	$6.31M	Hold	6,348	–	–	0.51%	12
2018 Q4	$5.51M	Hold	6,348	–	–	0.57%	15
2018 Q3	$6.56M	Hold	6,348	–	–	0.48%	19
2018 Q2	$5.83M	Sell	6,348 -800	-11%	-$859K	0.48%	19
2018 Q1	$6.97M	Sell	7,148 -8,800	-55%	-$8.02M	0.77%	17
2017 Q4	$7.22M	Hold	15,948	–	–	0.87%	17
2017 Q3	$6.6M	Hold	15,948	–	–	0.92%	15
2017 Q2	$5.58M	Hold	15,948	–	–	0.94%	13
2017 Q1	$8.19M	Hold	15,948	–	–	1.63%	13
2016 Q4	$5.66M	Hold	15,948	–	–	1.01%	13
2016 Q3	$8.53M	Hold	15,948	–	–	1.22%	13
2016 Q2	$8.97M	Hold	15,948	–	–	1.45%	13
2016 Q1	$7.59M	Buy	15,948 +200	+1%	+$90K	1.05%	17
2015 Q4	$10.4M	Buy	15,748 +6,480	+70%	+$4.9M	1.48%	14
2015 Q3	$7.29M	Buy	9,268 +3,050	+49%	+$3.72M	1.06%	14
2015 Q2	$8.2M	Buy	+6,218	New	+$7.13M	0.94%	16

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

12 West Capital Management's ATRA Position: Q4 2020 in Review

12 West Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 6,348 shares — an estimated $2.06M sold.

12 West Capital Management first reported a position in ATRA in Q2 2015 and held it in 22 quarters. The position peaked at $10.4M in Q4 2015. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

12 West Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
12 West Capital Management sold 6,348 Atara Biotherapeutics shares in Q4 2020, an estimated $2.06M.
12 West Capital Management first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 22 quarters.
12 West Capital Management's Atara Biotherapeutics position peaked at $10.4M in Q4 2015.
148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on 12 West Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.